Monoclonal antibodies reveal additional epitopes of serotype D Cryptococcus neoformans capsular glucuronoxylomannan that elicit protective antibodies.
Epitope specificity and isotype influence mAb efficacy against Cryptococcus neoformans; however, the relative contribution of each attribute is poorly understood. To date, only mAbs that recognize two epitopes of capsular glucuronoxylomannan (GXM), defined by the IgG1 mAbs 2H1 and E1, consistently mediate protection against C. neoformans. The role of epitope specificity was further examined using six additional IgG1 mAbs and serotype D C. neoformans ATCC 24067. mAbs 3C2, 439, and 471 recognize the 2H1 epitope, whereas mAbs 339, 1255, and 302 recognize two separate epitopes. mAbs 3C2, 439, and 471 competed for GXM with the IgA mAb 18G9, a 2H1 mAb family member, whereas mAbs 302, 339, and 1255 did not. Each mAb bound GXM similarly, as determined by agglutination, direct Ag binding, Ag inhibition, and indirect capsular immunofluorescence assays. mAb apparent affinity constants for GXM ranged from 5 to 26 x 10(7) M(-1) with mAb 1255 > 3C2 > 339 > 439 > 471 > 302. Each mAb significantly prolonged survival (p < 0.05); the average survival times of control and mice passively immunized with mAbs 3C2, 302, 339, 439, 471, and 1255 were 10.8, 36.6, 33, 25.5, 24.9, 17, and 22.6 days, respectively. Although each mAb enhanced J774.16 cell fungicidal activity, differences were observed in the ability of each mAb to facilitate attachment and ingestion of cryptococci. These results indicate 1) two additional epitope specificities associated with mAb efficacy, 2) differences in opsonic and protective efficacy for IgG1 anti-GXM mAbs, 3) an association between affinity and protective efficacy, and 4) additional support for association between an annular indirect capsular immunofluorescence pattern and mAb efficacy.
Mukherjee
J
J
Department of Medicine, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Kozel
T R
TR
Casadevall
A
A
D000372:Agglutination Tests; D000818:Animals; D000908:Antibodies, Fungal / Q000096:biosynthesis* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000378:metabolism; D000946:Antigens, Fungal / Q000276:immunology*; D001666:Binding Sites, Antibody; D003453:Cryptococcosis / Q000276:immunology* / Q000401:mortality / Q000628:therapy; D003455:Cryptococcus neoformans / Q000145:classification / Q000276:immunology*; D000939:Epitopes / Q000276:immunology*; D005260:Female; D051379:Mice; D008805:Mice, Inbred A; D011134:Polysaccharides / Q000276:immunology*; D012703:Serotyping; D016019:Survival Analysis
D000908:Antibodies, Fungal; D000911:Antibodies, Monoclonal; D000946:Antigens, Fungal; D000939:Epitopes; D011134:Polysaccharides; C027478:glucuronoxylomannan